Cogstate Ltd Announces Share Buy-Back Update

TipRanksApr 23 07:07

Enrolment Completed in Actinogen's XanaCIDD Phase 2a Cognition & Depression Trial

Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD

PR NewswireApr 22 20:30

Cogstate Ltd Continues Share Buy-Back Initiative

TipRanksApr 16 07:17

First Patient Treated in Actinogen's XanaMIA Phase 2b Alzheimer's Disease Trial

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease Enr

PR NewswireApr 15 20:30

Cogstate Ltd Continues Share Buy-Back Program

TipRanksApr 15 07:27

Cogstate (ASX:CGS) Shareholders Have Earned a 42% CAGR Over the Last Five Years

Yahoo FinanceApr 15 06:33